Patients

Suitable for a variety of patient populations2,3,20

WINLEVI® (clascoterone) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.2

Select a patient profile to learn more:

Adolescent males and females
Adolescent
males and females
In monotherapy as maintenance
In monotherapy as maintenance
Late onset / Hormonal acne
Late onset /
Hormonal acne
Menopausal Women
Menopausal
Women
Adolescent males and females
Depicted person is not an actual patient.

Adolescent males and females, 12 years and older

WINLEVI® is:

  • The first topical androgen-receptor inhibitor suitable for male and female patients 12 years of age and older.3,5
  • Rapidly metabolised in the skin to cortexelone, a naturally occurring hormone, limiting systemic absorption.2,21
In monotherapy as maintenance
Depicted person is not an actual patient.

In monotherapy as maintenance

WINLEVI® is:

  • WINLEVI® is the first topical androgen-receptor inhibitor indicated for treatment of acne vulgaris.1,2
  • WINLEVI® is rapidly metabolised in the skin to cortexelone, a naturally occurring hormone, limiting systemic absorption.2,21
Late onset / Hormonal acne
Depicted person is not an actual patient.

Late onset / hormonal acne, 25 years and older

WINLEVI® is:

  • The first topical licenced androgen-receptor inhibitor indicated for treatment of acne vulgaris.1,2
  • Rapidly metabolised in the skin to cortexelone, a naturally occurring hormone, limiting systemic absorption.2,21
Menopausal Women
Depicted person is not an actual patient.

Menopausal Women

WINLEVI® is:

  • A topical androgen-receptor inhibitor.2
  • Rapidly metabolised in the skin to cortexelone, a naturally occurring hormone, limiting systemic absorption.2,21
  • Therefore, WINLEVI® is suitable for treatment of acne during and after menopause.2

Application

USE TWICE DAILY

WINLEVI® CAN BE INCORPORATED INTO A PATIENT'S TWICE DAILY CLEANSING ROUTINE2

If patients forget to take a dose of WINLEVI® they should be instructed to apply the next dose at the usual time. Patients should be instructed to not apply a double dose to make up for forgotten doses.

A re-evaluation of patient treatment at 12 weeks should be considered if it is necessary to continue or restart treatment after this period and treatment should be continued after medical review and under regular supervision.

No interaction clinical studies, including interaction studies with other topical treatments, have been performed. Caution should be exercised in using WINLEVI® along other drugs known to suppress the HPA axis.

Please read the safety section and special warnings and precautions for use before prescribing.

NICE clinical knowledge summary:

“Advise people with acne to use a non-alkaline (skin pH neutral or slightly acidic) synthetic detergent cleansing product twice daily on acne-prone skin.” 22

Application

SKINTELLIGENCE
TWICE DAILY

WINLEVI® is easy to incorporate into
patients’ daily skin care routine.3

NICE clinical knowledge summary:

“Advise people with acne to use a non-alkaline (skin pH neutral or slightly acidic) synthetic detergent cleansing product twice daily on acne-prone skin.” 24

Explore more
Indication

WINLEVI® (clascoterone) 10 mg/g cream is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.2

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd medical_information@glenmarkpharma.com or call 0800 458 0383.

References

  1. Rosette C, et al. J Drugs Dermatol. 2019;18(5):412-418.
  2. WINLEVI® SPC.
  3. Eichenfield LF, et al. J Drugs Dermatol. 2024;23(1):1278-1283.
  4. Purdy S, DeBerker D. BMJ Clin Evid. 2008;1714.
  5. Zouboulis CC, Bettoli V. Br J Dermatol. 2015;Suppl 1:27-36.
  6. ONS. Estimates of the population for the UK, England, Wales, Scotland and Northern Ireland. Accessed 27 June 2024. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland.
  7. Primary Care Dermatology Society. Acne: acne vulgaris. Accessed 27 June 2024. https://www.pcds.org.uk/clinical-guidance/acne-vulgaris.
  8. Dawson AL, et al. BMJ. 2013;346:f2634.
  9. Layton AM, Thiboutot D, Tan J. Br J Dermatol. 2021;184(2):219-225.
  10. Morshed ASM, et al. Sci Rep. 2023; 13: 21084.
  11. Baldwin, H et al. J Drugs Dermatol. 2023;22(6):582-587.
  12. Del Rosso JQ, Kircik L. J Dermatolog Treat. 2024;35(1):2298878.
  13. Kurokawa I, et al. Dermatol Ther (Heidelb). 2021;11(4):1129-1139.
  14. Tuchayi S, et al. Acne vulgaris. Nat Rev Dis Primers. 2015; 1:15029.
  15. Kim HJ, et al. Int J Mol Sci. 2024;25(10):5302.
  16. Hebert A, et al. J Drugs Dermatol. 2023;22(2):174-181.
  17. Hebert A, et al. JAMA Dermatol. 2020;156(6):621-630.
  18. Abelson MB, Fink K. (2003). Controlling for the Placebo Effect. Review of Ophthalmology. Accessed October 2024.
  19. Hebert A, et al. JAMA Dermatology. 2020;156(6):621-630 (Supplement 1).
  20. Eichenfield L, et al. J Am Acad Dermatol. 2020;83(2):477-485.
  21. Mazzetti A, et al. J Drugs Dermatol. 2019;18(6):563.
  22. NICE Clinical Knowledge Summary. Acne vulgaris.

Depicted people are not actual patients.

For market research purposes only